Advertisement

Highlights From the SSO 2023 International Conference on Surgical Cancer Care


On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we’ll share results of the SWOG S1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then, we'll hear about a study that aimed to evaluate whether personalized ctDNA profiling could aid in identifying recurrence in patients with soft-tissue sarcomas.




Advertisement
Advertisement

Advertisement



Advertisement